Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative evaluation of automated MRI-based brain volumetry software for estimating cognitive domains in early Alzheimer's disease.

BMC medical imaging·2026
Same author

Prediction of FLAIR MRI from <sup>18</sup>F-FDG PET/CT for the Evaluation of White Matter Hyperintensity Using Generative Adversarial Network.

Journal of imaging informatics in medicine·2026
Same author

Association of White Matter Hyperintensities, Regional Brain Glucose Metabolism, and Cognitive Impairment in Aβ-Negative Patients.

Neurology·2026
Same author

A quantitative DOPA decarboxylase biomarker for diagnosis in Lewy body disorders.

Nature medicine·2026
Same author

Effect of tau burden and Lewy pathology on neuropsychiatric symptoms in Aβ-positive individuals.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Putaminal hypermetabolism identifies Lewy body co-pathology in Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Young-Gun Lee1

  • 1Ilsan Paik Hospital, Inje University College of Meidicine, Goyang, Gyeonggi, Korea, Republic of (South).

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 25, 2025
PubMed
Summary
This summary is machine-generated.

Discrepancies between clinical and biological staging in Alzheimer's disease (AD) predict prognosis. Patients with worse clinical stage showed faster decline and higher risk, while better clinical stage indicated lower risk.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Area of Science:

  • Neuroscience
  • Neurology
  • Biomarkers

Background:

  • Alzheimer's disease (AD) exhibits significant heterogeneity.
  • Integrating clinical and biological staging may elucidate factors contributing to AD variability.

Purpose of the Study:

  • To investigate the prognostic implications of integrating clinical and biological staging in Alzheimer's disease.
  • To classify participants based on the discrepancy between cognitive and tau deposition stages.

Main Methods:

  • Utilized data from 193 participants in the Alzheimer's Disease Neuroimaging Initiative.
  • Measured the discrepancy between clinical (cognition) and biological (tau deposition) stages using W-scores.
  • Classified participants into concordant (W0), worse clinical (W-), and better clinical (W+) stage groups.

Main Results:

  • The W- group exhibited faster cognitive decline and increased progression risk (HR=2.40).
  • The W+ group demonstrated a lower progression risk (HR=0.43).
  • Co-pathology burden correlated with W-scores, with the W- group showing higher cerebrospinal α-synuclein positivity and lower brain metabolism.

Conclusions:

  • An integrated staging scheme for Alzheimer's disease has significant clinical utility.
  • This approach aids in predicting AD prognosis and understanding underlying co-pathologies.